pacbio stock — Pacific Biosciences (PACB) Guide
Pacific Biosciences (PACB) — Stock
This article covers pacbio stock — the common shares of Pacific Biosciences of California, Inc. — and explains what the company does, where PACB trades, how to read key market and financial data, common business drivers and risks, and where to find timely quotes, charts and filings. If you are researching pacbio stock for the first time, this guide provides a structured, neutral reference and points to primary sources for live figures and filings.
Company overview
Pacific Biosciences is a life‑sciences company focused on long‑read DNA sequencing technologies. pacbio stock represents equity ownership in a company that develops single‑molecule, real‑time (SMRT) sequencing systems and related consumables. The company’s instruments (historically Sequel and Revio families) and high‑fidelity (HiFi) long‑read workflows target research labs, clinical genomics groups, pharmaceutical and agricultural customers.
Founded in the early 2000s, Pacific Biosciences is headquartered in the United States and has a global customer base spanning academia, clinical labs and industry partners. The company’s business model typically combines initial instrument sales with recurring revenue from consumables, reagents and service contracts — a common setup among instrument‑centric life‑science firms. Investors and users often follow pacbio stock to track adoption of HiFi sequencing and new product launches.
Stock identifiers and listings
- Ticker: PACB (commonly quoted as PACB on U.S. exchanges). pacbio stock trades on Nasdaq.
- Primary exchange: Nasdaq (U.S.).
- International Securities Identification Number (ISIN) and other formal identifiers are available in SEC filings and on the company investor relations pages.
- Trading hours: Regular U.S. market hours (pre‑market and after‑hours sessions also provide quotes). Note that live session availability depends on the data provider.
- ADRs/secondary listings: pacbio stock is primarily a U.S. listed common stock; investors should verify if local brokers offer derivatives or fractional access.
Market profile and trading data
pacbio stock is typically categorized in a small‑cap to mid‑cap band depending on market conditions and recent share price. Key market profile items investors and researchers commonly check include market capitalization, float and shares outstanding, and average daily trading volume.
Where to find live market data and quote metrics for pacbio stock: major financial portals and market data providers — including Yahoo Finance, Nasdaq, TradingView, CNBC, MarketWatch, Robinhood, Zacks and CNN Markets — display real‑time (or delayed) quotes, charts and commonly used metrics such as market cap, volume, P/E when applicable, and forward estimates. For the latest numerical figures, consult those sources and the company’s investor relations updates. As of 2026‑01‑27, up‑to‑date market metrics for pacbio stock should be checked on a live data provider because market capitalization and volume change daily.
Historical price performance
Historical trends for pacbio stock include multi‑year swings tied to product announcements, earnings releases, biotech sector sentiment and broader market trends. Pacific Biosciences has experienced elevated volatility in the past as adoption of long‑read sequencing technologies and capital markets sentiment have shifted.
To review time‑series price performance, use interactive charts on TradingView, Nasdaq advanced charts, Yahoo Finance or MarketWatch. These tools allow users to inspect weekly, monthly and multi‑year views, overlay technical indicators and compare PACB to peer tickers or sector indices. For traders and longer‑term investors, examining split‑adjusted historical charts and trading volume patterns can help place recent price moves into context.
Financials and fundamentals
Key financial areas to research for pacbio stock include revenue growth (instrument sales and consumables), gross margin trends, operating expenses (research & development and sales & marketing), cash position and debt. Pacific Biosciences historically invested heavily in R&D and commercialization of long‑read sequencing systems; as a result, net income has at times been negative while the company prioritized growth and product rollouts.
Primary sources for verified financial statements: SEC filings (10‑Q, 10‑K), the company Investor Relations releases, and financial portals such as Yahoo Finance, Zacks and MarketWatch. These sources provide balance sheet, income statement and cash flow details, plus commonly used ratios (P/S, EV/Revenue, and, when applicable, P/E).
Note: financial figures change with each quarter’s release. Always cross‑check numbers against the company’s official filings on SEC EDGAR and the latest earnings presentation when assessing pacbio stock fundamentals.
Business drivers and growth strategy
Understanding the core drivers of pacbio stock requires a look at product portfolio, revenue mix and market opportunities:
-
Product portfolio: Pacific Biosciences markets sequencing instruments (hardware) and the consumables, reagents and bioinformatics workflows that support sequencing runs. The HiFi long‑read technology aims to provide highly accurate long reads that are valuable for complex genome assemblies, structural variation detection and certain clinical applications.
-
Recurring revenue: A significant portion of long‑term value comes from consumables and service contracts; steady instrument placements can result in recurring reagent purchases.
-
R&D and commercialization: Continued investment in instrument performance, throughput (e.g., higher‑throughput models) and workflow simplification are common strategic priorities that can affect adoption and, by extension, pacbio stock sentiment.
-
Market opportunities: Clinical sequencing (rare disease, oncology), large‑scale population genomics, microbial and agricultural genomics can drive demand for long‑read data. Partnerships with research consortia and pharmaceutical companies also influence adoption curves.
Recent developments and news
For up‑to‑date coverage of pacbio stock, monitor quarterly earnings releases, product announcements, regulatory clearances, commercial partnerships and analyst notes. Examples of the types of developments to track include new instrument launches, partnerships with sequencing service providers or research consortia, and quarterly revenue guidance updates.
-
As of 2026‑01‑27, according to Yahoo Finance and Nasdaq listings, investors should consult the company’s most recent earnings release and SEC filings for verified financial and corporate updates. (Check the investor relations page and SEC EDGAR for exact dates and filing texts.)
-
News aggregators and financial portals (e.g., CNBC, Zacks, MarketWatch, CNN Markets) often report headline items such as earnings beats/misses, revised guidance and analyst price‑target changes that impact pacbio stock.
When reading recent news about pacbio stock, note the reporting date and source. Example phrasing to look for in news feeds: “As of [date], according to [source], Pacific Biosciences reported …” This ensures time‑stamped context for any market reaction.
Analyst coverage and investor sentiment
Analyst coverage for pacbio stock may include buy/hold/sell ratings, price targets and model estimates published by sell‑side research teams. Aggregators like Zacks, Yahoo Finance and CNN Markets summarize analyst consensus and revisions. Institutional investor activity (13F filings) and notable stakeholder disclosures can also move sentiment.
Retail sentiment can be gauged through community platforms such as Stocktwits and TradingView community ideas; these sources reflect a range of viewpoints and shorter‑term trade ideas. Remember that sentiment indicators are descriptive, not prescriptive: they show what market participants are discussing but do not constitute investment recommendations.
Trading and technical analysis
Traders who monitor pacbio stock often use standard technical indicators (moving averages, RSI, MACD, volume profiles) and chart patterns to form short‑term views. TradingView and Nasdaq advanced charts provide a wide set of technical tools and community annotations.
Common technical observations include volatility spikes around earnings and news, and short‑term momentum changes after product announcements. Any technical read should be treated as informational; historical patterns do not guarantee future outcomes.
Risks and controversies
pacbio stock, like other biotech/instrument companies, is subject to a set of sector‑specific and market risks:
- Commercial adoption risk: Slower-than-expected adoption of new instruments or workflows can pressure revenues.
- Capital intensity: Investment in R&D and production capacity can increase cash burn, especially if revenue growth does not keep pace.
- Profitability: Continued operating losses are possible during heavy reinvestment phases.
- Dilution risk: Equity raises to fund operations may dilute existing shareholders.
- Regulatory and reimbursement risks: Clinical adoption in regulated markets depends on appropriate regulatory clearances and reimbursement environments.
- Market volatility: pacbio stock can be volatile, responding to biotech sector moves, broader equities markets and company‑specific news.
Any reported controversies or legal matters should be confirmed via SEC filings and reputable news outlets (e.g., CNBC, MarketWatch) before drawing conclusions.
Valuation metrics and comparison with peers
Common valuation metrics used for pacbio stock include:
- Price/Earnings (P/E): Only applicable if the company reports positive earnings; many growth‑oriented biotech tool companies have negative EPS, making P/E non‑applicable.
- Price/Sales (P/S): Useful for companies with negative earnings; compares market cap to revenue.
- Enterprise Value / Revenue (EV/Revenue): Adjusts for cash and debt to provide a capital structure‑aware multiple.
- Gross margin and operating margin trends: Indicative of how consumables and instrument sales mix affects profitability.
Peers and comparables for benchmarking may include other sequencing instrument providers and life‑science tools companies. When comparing pacbio stock to peers, adjust for business model differences (e.g., consumables mix, installed base, clinical focus).
Corporate governance and management
Corporate governance for pacbio stock holders is documented in the company’s investor relations section and proxy materials filed with the SEC. Key areas to review:
- Executive leadership: CEO, CFO and functional heads and their industry track records.
- Board composition: Independence, committee structure and governance policies.
- Governance documents: Bylaws, corporate governance guidelines and charters (available in proxy statements and investor relations materials).
For verified biographies and governance details, consult the latest proxy statement and the investor relations website.
Shareholder information
Shareholders who follow pacbio stock typically monitor:
- Major holders and institutional ownership: Available via 13F filings and institutional holdings summaries on Nasdaq and financial portals.
- Insider transactions: Reported on SEC Form 4 filings and summarized on broker or financial portal pages.
- Dividend policy: Historically, many growth‑oriented biotech tool companies do not pay dividends; confirm current policy in investor communications.
- Shareholder meetings and proxy materials: Filed with the SEC and published on the company’s investor relations page.
All shareholder disclosures are public via SEC EDGAR and the company’s investor relations materials; check filing dates to ensure timeliness.
Where to find quotes, filings and charts
Primary sources and platforms to track pacbio stock include:
- Yahoo Finance (PACB quotes and financial summaries)
- TradingView (interactive charting and community ideas)
- Nasdaq (official listings and advanced charts)
- CNBC (news and market commentary)
- MarketWatch (quotes and news summaries)
- Zacks (analyst and earnings summaries)
- Robinhood (retail quotes and basic metrics)
- Stocktwits (community sentiment and trade ideas)
- CNN Markets (quote and analyst overviews)
- SEC EDGAR (official filings: 10‑Q, 10‑K, 8‑K, proxy statements)
- Company Investor Relations (official press releases and presentations)
If you want to trade or research securities using an integrated platform, consider exploring Bitget for available research tools and trading capabilities. For legal and operational details regarding trading availability of non‑crypto securities, consult your broker and local regulations.
See also
- Long‑read sequencing
- SMRT technology
- Genome sequencing industry
- Competitor companies and life‑science instrument providers
References
Note: the following sources are commonly used to compile market and news data for pacbio stock. For any numeric metric or material event, check the source and the reported date.
- Yahoo Finance — PACB (quotes, market cap, financials)
- TradingView — PACB charting and community ideas
- Nasdaq — PACB listing and filings
- CNBC — PACB news summaries and market commentary
- MarketWatch — PACB quotes and company news
- Zacks — analyst summaries and earnings data
- Robinhood — PACB basic metrics and quote
- Stocktwits — retail sentiment and trade messages
- CNN Markets — PACB quote & forecasts
As of 2026‑01‑27, according to the above providers, users should consult the individual platform headlines and the company’s SEC filings for time‑stamped numeric updates.
External links
(Non‑clickable references — visit these sources by searching their names and PACB)
- Pacific Biosciences Investor Relations (company site)
- PACB on Yahoo Finance
- PACB on TradingView
- PACB listing information on Nasdaq
- SEC EDGAR filings for Pacific Biosciences
Further exploration: if you want live quotes, consider checking a market data provider and review the latest SEC filings for pacbio stock. To combine trading with research, explore Bitget’s platform and Bitget Wallet for integrated account and research tools where available. Remember: this article is informational and not investment advice — confirm all figures with primary sources before making decisions.
